Kinghorn Cancer Centre

What Kinghorn Cancer Centre does

The Kinghorn Cancer Centre (TKCC) is a non-profit translational oncology centre established in 2012 as a partnership between the Garvan Institute of Medical Research and St Vincent's Hospital Sydney, located at 370 Victoria Street, Darlinghurst, NSW. It delivers personalised cancer medicine spanning medical oncology, haematology, cancer genetics, clinical trials, theranostics, and cellular therapies (including CAR T-Cell), supported by multidisciplinary teams across 11 cancer types and allied services (clinical psychology, dietetics, social work, cancer care coordination). The centre's research programs — Cancer Ecosystems and Cancer Plasticity and Dormancy — focus on hard-to-treat cancers (breast, prostate, pancreatic) and have produced 770+ peer-reviewed discoveries, including the Breast Cancer Cell Atlas Consortium's single-cell map of over one million cells.

Operationally, TKCC runs one of Australia's busiest Phase 1 clinical trials units and leads the NSW Phase 1 consortium (NECTA), contributing to 50+ trials in 2024. It is the largest site in New South Wales for novel cancer clinical trial delivery, serves over 2,000 families through its Cancer Genetics Service across NSW, and has supported more than 25,000 patients over the past decade, with 25%+ from rural areas. The centre is part of St Vincent's Research Precinct, with governance shared between the two founding partners and fundraising conducted via St Vincent's Curran Foundation.

The business model is referral-driven and publicly funded: services are delivered within the Australian public healthcare system, paid through Medicare and St Vincent's Hospital Sydney arrangements, with no private pricing disclosed. Go-to-market relies on medical professional referrals (GPs and specialists) plus institutional partnerships with national and international consortia (AGCMC, ANZUP, COGNO, ICGC, ANZ Breast Cancer Trials Group), supplemented by social media presence on LinkedIn, X, and Facebook. The entity is not publicly listed, has no disclosed funding rounds, and operates as a non-profit.

Name

Kinghorn Cancer Centre

Legal name

The Kinghorn Cancer Centre

Website

https://tkcc.org.au

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

The Kinghorn Cancer Centre is a non-profit translational oncology partnership between the Garvan Institute and St Vincent's Hospital Sydney, delivering personalised cancer treatment, Phase 1 clinical trials, theranostics, cellular therapies, and cancer genetics services to patients across New South Wales.

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Cancer treatment services
• Oncology clinical trials
• Personalised cancer medicine
• Translational cancer research
• Cellular therapy services

Headquarters

HQ city

Darlinghurst

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Clinical Services Revenue: The Kinghorn Cancer Centre operates as part of St Vincent's Hospital Sydney, a major tertiary public hospital. Services are delivered within the Australian public healthcare system, funded through Medicare and public hospital arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The Kinghorn Cancer Centre delivers personalised cancer treatment to patients by integrating cutting-edge research from the Garvan Institute of Medical Research with clinical expertise from St Vincent's Hospital Sydney. It provides medical oncology, haematology, cancer genetics, clinical trials (including Phase 1), theranostics, cellular therapies, and supportive care services (psychology, dietetics, social work) across 11 cancer types.

Product overview

The Kinghorn Cancer Centre is a partnership between the Garvan Institute of Medical Research and St Vincent's Hospital Sydney, providing integrated personalised cancer treatment from bench to bedside. The Centre operates as a unified clinical and research facility offering medical oncology, haematology, cancer genetics, clinical trials, theranostics, cellular therapies, and supportive care services (clinical psychology, dietetics, social work). The Centre houses multidisciplinary teams across 11 cancer types and maintains active research programs including Cancer Ecosystems and Cancer Plasticity and Dormancy. Patients benefit from seamless integration of cutting-edge research with comprehensive clinical care including access to Phase 1 clinical trials, making it the largest site for novel cancer clinical trials delivery in NSW.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology Services Expert, compassionate, research-driven cancer care delivered by medical oncologists led by Professor Anthony Joshua, covering diagnosis, treatment planning, and multidisciplinary team review for solid tumour cancers.
• Haematology Services Specialised care for haematological cancers including leukaemia, lymphoma, multiple myeloma, and conditions affecting the bone marrow and lymphatic system, including bone marrow transplant and cellular therapies.
• Cancer Genetics Service Genetic counselling, evidence-based advice, and cancer genetic testing for eligible individuals and families, providing personalised guidance across more than 2,000 families throughout NSW.
• Clinical Trials Program One of Australia's most advanced oncology clinical trials programs with strong early-phase (Phase 1 and 2) capabilities; researchers contributed to more than 50 clinical trials in 2024 across multiple cancer types.
• Theranostics Advanced approach combining diagnostic imaging and targeted radiotherapy using radiopharmaceuticals that bind to cancer cells, allowing continuous monitoring and treatment of prostate cancer, thyroid cancer, and neuroendocrine tumours.
• Cellular Therapies Cellular therapies including CAR T-Cell therapy that use genetically modified cells from patients or donors to improve cancer-tracking and cancer-attacking ability.
• Research Programs Multi-disciplinary research including Cancer Ecosystems, Cancer Plasticity and Dormancy, breast cancer genomics (over one million cells sequenced), and international collaborations across pancreatic, prostate, and breast cancer.
• Clinical Psychology

Quantifiable outcome

• Supported over 25,000 patients in the last decade with over 25% from rural areas
• +3 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core, major and minor.

• Garvan Institute of Medical ResearchcoreStrategic or Co-development Partner · 1 January 2012The Kinghorn Cancer Centre is a partnership between Garvan Institute of Medical Research and St Vincent's Hospital Sydney, established in 2012 to bring together cutting-edge research and clinical expertise for personalised cancer treatment. Garvan researchers work to develop new diagnostic tools, treatments, and preventative approaches for various cancer types.
• St Vincent's Hospital SydneycoreStrategic or Co-development Partner · 1 January 2012The Kinghorn Cancer Centre operates as part of St Vincent's Hospital Sydney, providing seamless access to comprehensive services including medical and surgical specialists, emergency care, intensive care, outpatient clinics, and comprehensive cancer support.
• Sydney Catalyst Translational Cancer Research CentremajorStrategic or Co-development PartnerCollaborative partnership with Sydney Catalyst for translational cancer research.
• International Cancer Genome ConsortiummajorStrategic or Co-development PartnerLeading role in the International Cancer Genome Consortium for cancer genome research.
• Australian Epigenome AlliancemajorStrategic or Co-development PartnerCollaboration with Australian Epigenome Alliance for epigenetics research.
• Australian Prostate Cancer CollaborationmajorStrategic or Co-development PartnerPartnership for prostate cancer research and clinical trials.
• Australian Pancreatic Cancer Genome InitiativemajorStrategic or Co-development PartnerCollaborative research initiative for pancreatic cancer genome research.
• Australian and New Zealand Breast Cancer Trials GroupmajorStrategic or Co-development PartnerCollaboration in breast cancer clinical trials research.
• International Breast Cancer Study GroupmajorStrategic or Co-development PartnerInternational collaboration for breast cancer research and clinical trials.
• St Vincent's Centre for Applied Medical ResearchcoreStrategic or Co-development PartnerHome to Haematology Research Laboratories dedicated to advancing understanding of blood-related diseases and improving patient outcomes.
• Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)majorStrategic or Co-development PartnerTKCC researchers participate in ANZUP with Professor Anthony Joshua serving as Assistant Director of the translational science program.
• Australian Genomics Cancer Medicine Centre (AGCMC)majorStrategic or Co-development PartnerA nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine.
• New South Wales Early Phase Clinical Trials Alliance (NECTA)majorStrategic or Co-development PartnerTKCC leads the NSW Phase 1 clinical trials consortium NECTA.
• GenesisCaremajorStrategic or Co-development PartnerJoint Skin and Melanoma Multidisciplinary Team between The Kinghorn Cancer Centre and GenesisCare for skin cancer case discussions.
• ANZCTR (Australian New Zealand Clinical Trials Registry)minorOthersANZCTR is an online register of clinical trials; TKCC trials are registered on this platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Global leader in translational oncology, early-phase trials, and precision medicine. Functions as a benchmark and aspirational peer for TKCC's bench-to-bedside model and provides an international comparator for research and clinical trial scale.

Direct peers

• Icon Group (Icon Cancer Care): Australian-headquartered operator of cancer centres across Australia and Asia, offering medical oncology, radiation, and clinical trials. Competes for NSW referrals and is scaling theranostics and cellular therapy capability nationally.
• Chris O'Brien Lifehouse: Comprehensive cancer hospital in Sydney operating as a public-private partnership with the University of Sydney. Closest geographic peer to TKCC, offering medical oncology, surgery, radiation, survivorship, and clinical trials for the same Sydney patient population.
• GenesisCare: Australia's largest private oncology provider offering radiation oncology, theranostics, and medical oncology across a national network. Directly competes on theranostics and radiation, and is already partnered with TKCC via the joint Skin and Melanoma MDT.
• Sydney Cancer Centre (Royal Prince Alfred Hospital): Public comprehensive cancer centre within Sydney Local Health District, delivering medical and radiation oncology and clinical trials. Competes for the same Sydney metropolitan and rural NSW referral base as TKCC.
• Peter MacCallum Cancer Centre: Australia's largest dedicated cancer hospital, headquartered in Melbourne. Operates comprehensive medical, surgical, radiation oncology and a major early-phase trial unit; directly comparable as a translational research-driven comprehensive cancer centre competing for the same talent, trial sponsors, and patients.
• Olivia Newton-John Cancer Wellness & Research Centre: Comprehensive cancer centre at Austin Health in Melbourne combining clinical care, research, and wellness programs. Comparable translational model partnered with the Olivia Newton-John Cancer Research Institute, competing for national trial and research funding.
• Westmead Hospital Cancer Centre: Major western Sydney public cancer centre with multidisciplinary tumour streams and an active clinical trials program. Regional peer competing for Greater Sydney oncology referrals and research talent.

Others

• Garvan Institute of Medical Research: Core founding partner of TKCC and one of Australia's largest medical research institutes. Not a competitor but the research engine embedded within TKCC, sharing leadership and infrastructure.
• St Vincent's Hospital Sydney: TKCC's other founding partner and host public hospital within St Vincent's Health Network. Provides the inpatient, emergency, and surgical infrastructure that TKCC's cancer services depend on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/kinghorncancer
• Facebookfacebook.com/StVincentsHospitalSydney
• LinkedInlinkedin.com/company/the-kinghorn-cancer-centre

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinghorn Cancer Centre